With the FDA’s backing, Amarillo now aims to begin a 60-patient phase II study to test low-dose oral interferon as a treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) patients in the fourth quarter of 2006.
In other corporate developments, meanwhile, the company has announced that its study of oral warts in HIV patients has launched, with enrolment in the 80-patients phase II study expected to begin in September.
In other mid-stage trials news, Amarillo reported that enrollment in its phase II study of Behcet’s disease has reached 26 patients out of a targeted total of 90 patients. Additional sites are being added to the study with the goal of completing patient enrollment by the end of the year.
In order to help fund its IPF and oral warts studies, Amarillo recently completed a private placement, placing 1,200,000 shares of restricted stock for $660,000 with a European investor. This brings the total amount of capital raised in 2006 via the sale of restricted shares to $1,534,760.